FDA Drug Recalls

Recalls / Class II

Class IID-0390-2025

Product

Tirofiban Hydrochloride Injection 12.5 mg/250 mL (50 mcg/mL), 250 mL single-dose container (bag), Rx only, Manufactured in India for: Eugia U.S. LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ 08520, NDC 55150-430-01

Brand name
Tirofiban
Generic name
Tirofiban
Active ingredient
Tirofiban Hydrochloride
Route
Intravenous
NDCs
55150-429, 55150-430
FDA application
ANDA216379
Affected lot / code info
Lot# : 3TF24001, Exp 3/31/2026

Why it was recalled

Out-of-Specification test results were obtained in at long term conditions during 3 month's stability study for related substances.

Recalling firm

Firm
Eugia US LLC
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
279 Princeton Hightstown Rd, N/A, East Windsor, New Jersey 08520-1401

Distribution

Quantity
N/A
Distribution pattern
USA nationwide.

Timeline

Recall initiated
2025-04-21
FDA classified
2025-04-25
Posted by FDA
2025-05-07
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0390-2025. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.